INDIANAPOLIS, Oct. 13, 2010 (GLOBE NEWSWIRE) -- Positron Corporation (OTCBB:POSC), a leading molecular imaging company specializing in the field of nuclear cardiology, announced today it has placed orders for its sales of five Attrius™ PET scanners. The sales of these systems are for leading cardiology practices and hospitals. The Company also reported that with these orders, it expects to meet the high-end of its previously announced 2010 growth targets.
The Company noted that these current orders of five Attrius™ PET scanners are in addition to the ones previously announced in June and early September. With today's announcement, the Company fully anticipates it will reach the high-end of its previously stated sales goal of approximately 12 to 15 Attrius™ PET systems in 2010, equating to approximately $10 million to $12 million in sales, part of which will be recognized in the first quarter of 2011.
"We are pleased to report the orders of these additional systems, as well as the sales previously announced, as they serve as further evidence that mainstream cardiologists are embracing PET. The Attrius™ provides an elegant solution to managing coronary disease cost effectively; Positron is well-positioned to meet the rising demand and establish itself as a clear leader in cardiac PET," said Patrick G. Rooney, chief executive officer of Positron.
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius(TM), a PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the Tech-Assist(TM), a radiopharmaceutical injection shield. More information about Positron is available at .
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
CONTACT: Positron Corporation (317) 576-0183